Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elosulfase alfa.

Drugs of today (Barcelona, Spain : 1998) - 1 Jul 2014

Haddley K

Abstract excerpt

Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome, is an inherited, lysosomal storage disorder caused by genetic mutations in N-acetylgalactosamine-6-sulfatase (GALNS) enzyme gene. GALNS is essential for breakdown of glycosaminoglycans. The disease is characterized by the early onset of severe skeletal dysplasia resulting in significant disability by the second decade of life. Until...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mucopolysaccharidosis IV
Share to Mutation
Share to Recombinant Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Drug Evaluation, Preclinical

Share to Enzyme Replacement Therapy

Source

Identifiers

PMID: 25101330
DOI: 10.1358/dot.2014.50.7.2177904

Genes

GALNS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elosulfase alfa.PMID 25101330Read ↗

Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.Semantic proximity Read ↗

A Case Report of a Japanese Boy with Morquio A Syndrome: Effects of Enzyme Replacement Therapy Initiated at the Age of 24 Months.Semantic proximity Read ↗

Long-term Natural History and Elosulfase Alfa Treatment for Mucopolysaccharidosis Type IVA: A Single-Center Study in the Czech RepublicSemantic proximity Read ↗

Enzyme replacement therapy in a murine model of Morquio A syndromeSemantic proximity Read ↗

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.Semantic proximity Read ↗

Four novel mutations in the N-acetylgalactosamine-6-sulfate sulfatase gene among Egyptian patients with Morquio A disease.Semantic proximity Read ↗

Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment.Semantic proximity Read ↗

Clinical characteristics of patients from Quebec, Canada, with Morquio A syndrome: a longitudinal observational studySemantic proximity Read ↗

Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidanceSemantic proximity Read ↗

Diagnosing mucopolysaccharidosis IVA.Semantic proximity Read ↗

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).Semantic proximity Read ↗

Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.